An observational study in Ischemic Heart Disease, sponsored by National Taiwan University Hospital Hsin-Chu Branch. Recruiting at 1 site in Taiwan. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-01-05.
Sponsored by National Taiwan University Hospital Hsin-Chu Branch · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to test the feasibility of intracoronary adenosine administration during coronary flow reserve(CFR) and index of microcirculatory resistance(IMR) assessment in a population with angina. The main questions it aims to answer are:
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
This study's planned enrollment of 30 is below the median of 318 across 398 observational studies indexed under Myocardial Ischemia.
Browse Myocardial Ischemia studies →National Taiwan University Hospital Hsin-Chu Branch is the lead sponsor of 36 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants with angina and undergo invasive coronary angiography
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: CFR and IMR group
Participants will undergo repeat intracoronary adenosine administration during CFR and IMR measurement
Repeatability of CFR and IMR value
To compare the difference of individual value, while repeat the measurement within 1 minutes
Time frame: 10 minutes
Major adverse cardiovascular outcomes
Including death, myocardial infarction, stroke and heart failure
Time frame: 3 year
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2023; primary completion for Dec 2025, 35 months later.
Of 165 non-industry observational studies under Myocardial Ischemia, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 127. This study's planned 35 months is below that.
Counting every sponsor, half of 204 studies reached it within 40 months; a quarter within 21 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital Hsin-Chu Branch